Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation
Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation
The objectives of this study are:

 -  To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic
 decompensation events

 -  To evaluate the relationship between liver Biopsy and clinical outcome and show that the
 MBT has a better predictive ability of clinical outcome than liver biopsy.

 -  To evaluate the ability of the MBT to predict each of the individual liver related
 complications.
Exalenz has previously gathered information in a previous study on patients with chronic
 liver disease including the methacetin breath test. Several years later, the company wishes
 to investigate this group of subjects and see retrospectively if the breath test was a
 predictor of complications related to their liver disease.
Inclusion Criteria:

 All subjects that aere enrolled in the previous Exalenz trial HIS-EX-408 or PLT-BID-1108

 Exclusion Criteria:

 None